News & Updates

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are superior to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing renal outcomes among patients with type 2 diabetes (T2D) in Hong Kong, a real-world population-based study by the University of Hong Kong has shown.

The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.

Infants born to mothers who popped vitamin D during pregnancy are less likely to develop atopic eczema compared with their counterparts whose mothers received placebo, as shown in the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS).

Bioavailability studies presented at ENDO 2022 showed that patients with hypothyroidism can safely take the liquid formulations of levothyroxine (LT4) 15 or 30 minutes before meals, without having to worry about food effect on bioavailability.

Women who receive COVID-19 jabs may experience short-term changes in their menstrual cycle length, particularly those who have short, long, or irregular cycles prior to vaccination, a study has found.

Some medications may directly cause the occurrence of urinary tract infections (UTIs), and a recent study presented at the 37th Annual European Association of Urology Congress (EAU 2022) has identified six drugs that appear to contribute to “significant reporting levels” for infections.